The 340B Drug Pricing Program was created to help vulnerable patients access affordable medications by offering steep drug discounts to qualifying hospitals. The expectation was simple: savings would be used to expand care and lower costs for patients.

Today, that promise is often not being met. Many hospitals purchase drugs at deep discounts but continue to charge patients and insurers full price—keeping the difference instead of passing savings on at the pharmacy counter. In some cases, this has contributed to rising medical debt and aggressive collection practices against patients.

Without transparency and accountability, the program risks prioritizing institutional revenue over patient access. Reform is necessary to ensure 340B works as Congress intended.